Toll-like receptor 7 - Wikipedia
A TLR7 agonist, imiquimod (Aldara), [10] has been approved for topical use in treating warts caused by papillomavirus and for actinic keratosis. [11] Due to their ability to induce robust production of anti-cancer cytokines such as interleukin-12, TLR7 agonists have also been investigated for cancer immunotherapy and as vaccine adjuvants.
Applications and clinical trial landscape using Toll-like receptor ...
Mar 8, 2023 · Imiquimod is a topical TLR7 agonist, approved by the FDA for antiviral and skin cancer treatments. Other TLR adjuvants are used in several vaccines including Nu Thrax, Heplisav, T-VEC, and...
Targeting toll-like receptor 7/8 for immunotherapy: recent …
Dec 7, 2022 · GS-9620 is a potent oral TLR7 agonist, which can induce the secretion of cytokines and chemokines such as IFN-α, upregulate the expression of TLR7 and interferon-stimulated genes (ISGs) in PBMCs and liver tissue, activate NK-cells and T-cell subpopulations, and initiate an anti-viral immune response, significantly reducing serum levels of HBV ...
The role of TLR7 agonists in modulating COVID-19 severity in
Aug 11, 2023 · TLR7 agonists can efficiently bind to hypofunctional and neutral TLR7 variants and stimulate TLR7-MyD88-TIRAP mediated signaling to restore anti-viral responses.
The TLR7/8 agonist R848 remodels tumor and host responses to …
Oct 15, 2019 · We demonstrate that TLR7/8 agonist R848 induces anti-tumor responses and attenuates cachexia in murine models of pancreatic ductal adenocarcinoma (PDAC).
Toll-like Receptors and the Control of Immunity - Cell Press
This TLR7-8-9-driven IFN response in pDCs leads to IFNα secretion. pDCs express IRF7 at high levels, and phosphorylation of IRF7 by IKKα controls IRF7 homodimers driving IFNα expression. In addition to IRFs 3 and 7, IRFs 1 and 5 contribute to gene expression in the TLR pathways.
Recent trends in the development of Toll-like receptor 7/8
TLR7/8 agonists exhibit potent antiviral activity and regulate anti-tumor immune responses. TLR7 agonists have also been used as adjuvants to improve vaccine immunogenicity and generate greater seroprotection.
Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
The TLR7 agonist can enhance the production of IFN-γ in CD8 + T cells from mesenteric lymph node T cells in infected mice . Moreover, TLR7/MyD88-dependent signaling activation in CD8 + T cells can promote cellular glycolysis and enhance T cell effector functions ( 142 ).
Potential value of pharmacological agents acting on toll-like …
Nov 2, 2021 · TLR7/8 agonists as immuno-stimulants against SARS-CoV-2-induced mild-to-moderate COVID-19. TLR7/8, situated in endosomes, play a key role in the recognition of SARS-CoV-2 causing COVID-19.
Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA ...
Dec 18, 2018 · GS9620, a TLR7-specific agonist developed by Gilead Sciences, is now undergoing clinical trials and aims to cure HIV-1 and hepatitis B virus infections (Gane et al., 2015; Sloan et al., 2015, CROI, conference).